<drug type="biotech" created="2005-06-13" updated="2020-09-03">
  <drugbank-id primary="true">DB00078</drugbank-id>
  <drugbank-id>BTD00069</drugbank-id>
  <drugbank-id>BIOD00069</drugbank-id>
  <name>Ibritumomab tiuxetan</name>
  <description>Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each.</description>
  <cas-number>206181-63-7</cas-number>
  <unii>4Q52C550XK</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links>
      <link>
        <ref-id>L51</ref-id>
        <title>Link</title>
        <url>http://web.b.ebscohost.com/dynamed/detail?vid=6&amp;sid=48a6db20-234e-4280-b18e-dcd0e2fed388%40sessionmgr198&amp;hid=102&amp;bdata=JnNpdGU9ZHluYW1lZC1saXZlJnNjb3BlPXNpdGU%3d#db=dme&amp;AN=232878</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>For treatment of non-Hodgkin's lymphoma</indication>
  <pharmacodynamics>Ibritumomab is a murine monoclonal antibody against CD20 that has been radiolabeled with yttrium-90.</pharmacodynamics>
  <mechanism-of-action>The Fab segment of the antibody targets the CD20 epitope on B-cells, allowing the radioactive yttrium to destroy the cell via production of beta particles.</mechanism-of-action>
  <toxicity/>
  <metabolism>Most likely removed by opsonization via the reticuloendothelial system when bound to B cells, or by human antimurine antibody production</metabolism>
  <absorption/>
  <half-life>0.8 hours (mammalian reticulocytes, in vitro)</half-life>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution>Binding observed on lymphoid cells of the bone marrow, lymph node, thymus, red and white pulp of the spleen, lymphoid follicles of the tonsil, and lymphoid nodules of other organs (e.g., large and small intestines)</volume-of-distribution>
  <clearance>Approximately 7.2% of injected dose of yttrium Y 90 ibritumomab tiuxetan is excreted in urine within 7 days.</clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT001767</drugbank-id>
      <name>Indium In-111 ibritumomab tiuxetan</name>
      <unii>S9U4ZR2W8V</unii>
      <cas-number/>
      <inchikey/>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT001768</drugbank-id>
      <name>Yttrium y-90 ibritumomab tiuxetan</name>
      <unii>QA846JAV5B</unii>
      <cas-number/>
      <inchikey/>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">Ibritumomab</synonym>
    <synonym language="english" coder="">mAb Murine (IGG1) Anti P19437 (CD20_MOUSE)</synonym>
  </synonyms>
  <products>
    <product>
      <name>Zevalin</name>
      <labeller>Spectrum Pharmaceuticals B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000547</ema-product-code>
      <ema-ma-number>EU/1/03/264/001</ema-ma-number>
      <started-marketing-on>2004-01-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength>1.6 mg/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Zevalin</name>
      <labeller>Spectrum Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68152-104</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-02-19</started-marketing-on>
      <ended-marketing-on>2009-06-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength>1.6 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125019</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zevalin</name>
      <labeller>Spectrum Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68152-103</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-02-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength>1.6 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125019</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zevalin</name>
      <labeller>Acrotech Biopharma Llc</labeller>
      <ndc-id/>
      <ndc-product-code>72893-007</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-02-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength>1.6 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125019</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Zevalin</name>
      <ingredients>Ibritumomab tiuxetan</ingredients>
    </mixture>
    <mixture>
      <name>Zevalin</name>
      <ingredients>Ibritumomab tiuxetan</ingredients>
    </mixture>
    <mixture>
      <name>Zevalin</name>
      <ingredients>Ibritumomab tiuxetan</ingredients>
    </mixture>
    <mixture>
      <name>Zevalin</name>
      <ingredients>Ibritumomab tiuxetan</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Spectrum Pharmaceuticals</name>
      <url>http://www.spectrumpharm.com</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Zevalin in-111 kit</description>
      <cost currency="USD">4200.0</cost>
      <unit>kit</unit>
    </price>
    <price>
      <description>Zevalin y-90 kit</description>
      <cost currency="USD">37800.0</cost>
      <unit>kit</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Antibodies</category>
      <mesh-id>D000906</mesh-id>
    </category>
    <category>
      <category>Antigens, CD20</category>
      <mesh-id>D018951</mesh-id>
    </category>
    <category>
      <category>Blood Proteins</category>
      <mesh-id>D001798</mesh-id>
    </category>
    <category>
      <category>CD20-directed Antibody Interactions</category>
      <mesh-id/>
    </category>
    <category>
      <category>CD20-directed Radiotherapeutic Antibody</category>
      <mesh-id/>
    </category>
    <category>
      <category>Globulins</category>
      <mesh-id>D005916</mesh-id>
    </category>
    <category>
      <category>Immunoglobulins</category>
      <mesh-id>D007136</mesh-id>
    </category>
    <category>
      <category>Immunoproteins</category>
      <mesh-id>D007162</mesh-id>
    </category>
    <category>
      <category>Immunosuppressive Agents</category>
      <mesh-id>D007166</mesh-id>
    </category>
    <category>
      <category>Lymphoma, B-Cell</category>
      <mesh-id>D016393</mesh-id>
    </category>
    <category>
      <category>Myelosuppressive Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Radiopharmaceutical Activity</category>
      <mesh-id/>
    </category>
    <category>
      <category>Serum Globulins</category>
      <mesh-id>D012712</mesh-id>
    </category>
    <category>
      <category>Therapeutic Radiopharmaceuticals</category>
      <mesh-id/>
    </category>
    <category>
      <category>Various Therapeutic Radiopharmaceuticals</category>
      <mesh-id/>
    </category>
    <category>
      <category>Yttrium Radioisotopes</category>
      <mesh-id>D015021</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>3.23 g/L</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravenous; Parenteral</route>
      <strength>1.6 MG/ML</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route/>
      <strength>3.2 mg/2mL</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Intravenous</route>
      <strength>1.6 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Intravenous</route>
      <strength>1.6 mg/ml</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>3.2 mg</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="V10XX02">
      <level code="V10XX">Various therapeutic radiopharmaceuticals</level>
      <level code="V10X">OTHER THERAPEUTIC RADIOPHARMACEUTICALS</level>
      <level code="V10">THERAPEUTIC RADIOPHARMACEUTICALS</level>
      <level code="V">VARIOUS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00078.pdf?1265922794</fda-label>
  <patents>
    <patent>
      <number>2149329</number>
      <country>Canada</country>
      <approved>2008-07-15</approved>
      <expires>2013-11-12</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB06643</drugbank-id>
      <name>Denosumab</name>
      <description>The risk or severity of adverse effects can be increased when Denosumab is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00005</drugbank-id>
      <name>Etanercept</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00008</drugbank-id>
      <name>Peginterferon alfa-2a</name>
      <description>The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00011</drugbank-id>
      <name>Interferon alfa-n1</name>
      <description>The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00018</drugbank-id>
      <name>Interferon alfa-n3</name>
      <description>The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00022</drugbank-id>
      <name>Peginterferon alfa-2b</name>
      <description>The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00026</drugbank-id>
      <name>Anakinra</name>
      <description>The risk or severity of adverse effects can be increased when Anakinra is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00033</drugbank-id>
      <name>Interferon gamma-1b</name>
      <description>The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00034</drugbank-id>
      <name>Interferon alfa-2a, Recombinant</name>
      <description>The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00041</drugbank-id>
      <name>Aldesleukin</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00051</drugbank-id>
      <name>Adalimumab</name>
      <description>The risk or severity of adverse effects can be increased when Adalimumab is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00056</drugbank-id>
      <name>Gemtuzumab ozogamicin</name>
      <description>The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00059</drugbank-id>
      <name>Pegaspargase</name>
      <description>The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00065</drugbank-id>
      <name>Infliximab</name>
      <description>The risk or severity of adverse effects can be increased when Infliximab is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00068</drugbank-id>
      <name>Interferon beta-1b</name>
      <description>The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00069</drugbank-id>
      <name>Interferon alfacon-1</name>
      <description>The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00073</drugbank-id>
      <name>Rituximab</name>
      <description>The risk or severity of adverse effects can be increased when Rituximab is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00074</drugbank-id>
      <name>Basiliximab</name>
      <description>The risk or severity of adverse effects can be increased when Basiliximab is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00075</drugbank-id>
      <name>Muromonab</name>
      <description>The risk or severity of adverse effects can be increased when Muromonab is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00081</drugbank-id>
      <name>Tositumomab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tositumomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00087</drugbank-id>
      <name>Alemtuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Alemtuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00092</drugbank-id>
      <name>Alefacept</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Alefacept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00095</drugbank-id>
      <name>Efalizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Efalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00098</drugbank-id>
      <name>Antithymocyte immunoglobulin (rabbit)</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Antithymocyte immunoglobulin (rabbit).</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00105</drugbank-id>
      <name>Interferon alfa-2b</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Interferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00111</drugbank-id>
      <name>Daclizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Daclizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00112</drugbank-id>
      <name>Bevacizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bevacizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00120</drugbank-id>
      <name>Phenylalanine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Phenylalanine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00180</drugbank-id>
      <name>Flunisolide</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Flunisolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00188</drugbank-id>
      <name>Bortezomib</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bortezomib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00242</drugbank-id>
      <name>Cladribine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00262</drugbank-id>
      <name>Carmustine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Carmustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00276</drugbank-id>
      <name>Amsacrine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Amsacrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00290</drugbank-id>
      <name>Bleomycin</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bleomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00291</drugbank-id>
      <name>Chlorambucil</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Chlorambucil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00293</drugbank-id>
      <name>Raltitrexed</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Raltitrexed.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00305</drugbank-id>
      <name>Mitomycin</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mitomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00307</drugbank-id>
      <name>Bexarotene</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bexarotene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00309</drugbank-id>
      <name>Vindesine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vindesine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00322</drugbank-id>
      <name>Floxuridine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Floxuridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Indomethacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00352</drugbank-id>
      <name>Tioguanine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tioguanine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00361</drugbank-id>
      <name>Vinorelbine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vinorelbine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00380</drugbank-id>
      <name>Dexrazoxane</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dexrazoxane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00394</drugbank-id>
      <name>Beclomethasone dipropionate</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Beclomethasone dipropionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00398</drugbank-id>
      <name>Sorafenib</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sorafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00428</drugbank-id>
      <name>Streptozocin</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Streptozocin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00432</drugbank-id>
      <name>Trifluridine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Trifluridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00441</drugbank-id>
      <name>Gemcitabine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Gemcitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00443</drugbank-id>
      <name>Betamethasone</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Betamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00444</drugbank-id>
      <name>Teniposide</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Teniposide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00445</drugbank-id>
      <name>Epirubicin</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Epirubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00446</drugbank-id>
      <name>Chloramphenicol</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Chloramphenicol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00480</drugbank-id>
      <name>Lenalidomide</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lenalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00488</drugbank-id>
      <name>Altretamine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Altretamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00495</drugbank-id>
      <name>Zidovudine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Zidovudine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00515</drugbank-id>
      <name>Cisplatin</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cisplatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00526</drugbank-id>
      <name>Oxaliplatin</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Oxaliplatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00531</drugbank-id>
      <name>Cyclophosphamide</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cyclophosphamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00541</drugbank-id>
      <name>Vincristine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vincristine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00544</drugbank-id>
      <name>Fluorouracil</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00550</drugbank-id>
      <name>Propylthiouracil</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Propylthiouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00552</drugbank-id>
      <name>Pentostatin</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pentostatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00563</drugbank-id>
      <name>Methotrexate</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Methotrexate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00564</drugbank-id>
      <name>Carbamazepine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Carbamazepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00570</drugbank-id>
      <name>Vinblastine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vinblastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00588</drugbank-id>
      <name>Fluticasone propionate</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluticasone propionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00591</drugbank-id>
      <name>Fluocinolone acetonide</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluocinolone acetonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00601</drugbank-id>
      <name>Linezolid</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Linezolid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00619</drugbank-id>
      <name>Imatinib</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Imatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00620</drugbank-id>
      <name>Triamcinolone</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Triamcinolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00631</drugbank-id>
      <name>Clofarabine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Clofarabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00635</drugbank-id>
      <name>Prednisone</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Prednisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00642</drugbank-id>
      <name>Pemetrexed</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pemetrexed.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00687</drugbank-id>
      <name>Fludrocortisone</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fludrocortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00688</drugbank-id>
      <name>Mycophenolate mofetil</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mycophenolate mofetil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00694</drugbank-id>
      <name>Daunorubicin</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Daunorubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00755</drugbank-id>
      <name>Tretinoin</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tretinoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00762</drugbank-id>
      <name>Irinotecan</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Irinotecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00763</drugbank-id>
      <name>Methimazole</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Methimazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00773</drugbank-id>
      <name>Etoposide</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Etoposide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00795</drugbank-id>
      <name>Sulfasalazine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sulfasalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00851</drugbank-id>
      <name>Dacarbazine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dacarbazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00853</drugbank-id>
      <name>Temozolomide</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Temozolomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00859</drugbank-id>
      <name>Penicillamine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Penicillamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00860</drugbank-id>
      <name>Prednisolone</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Prednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00877</drugbank-id>
      <name>Sirolimus</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sirolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00888</drugbank-id>
      <name>Mechlorethamine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mechlorethamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00928</drugbank-id>
      <name>Azacitidine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Azacitidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00958</drugbank-id>
      <name>Carboplatin</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Carboplatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00959</drugbank-id>
      <name>Methylprednisolone</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Methylprednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00970</drugbank-id>
      <name>Dactinomycin</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dactinomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00987</drugbank-id>
      <name>Cytarabine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cytarabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00993</drugbank-id>
      <name>Azathioprine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Azathioprine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00997</drugbank-id>
      <name>Doxorubicin</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Doxorubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01005</drugbank-id>
      <name>Hydroxyurea</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Hydroxyurea.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01008</drugbank-id>
      <name>Busulfan</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Busulfan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01024</drugbank-id>
      <name>Mycophenolic acid</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mycophenolic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01030</drugbank-id>
      <name>Topotecan</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Topotecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01033</drugbank-id>
      <name>Mercaptopurine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mercaptopurine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01041</drugbank-id>
      <name>Thalidomide</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Thalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01042</drugbank-id>
      <name>Melphalan</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Melphalan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01073</drugbank-id>
      <name>Fludarabine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fludarabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01099</drugbank-id>
      <name>Flucytosine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Flucytosine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01101</drugbank-id>
      <name>Capecitabine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Capecitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01108</drugbank-id>
      <name>Trilostane</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Trilostane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01168</drugbank-id>
      <name>Procarbazine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Procarbazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01169</drugbank-id>
      <name>Arsenic trioxide</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Arsenic trioxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01177</drugbank-id>
      <name>Idarubicin</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Idarubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01181</drugbank-id>
      <name>Ifosfamide</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ifosfamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01196</drugbank-id>
      <name>Estramustine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Estramustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01204</drugbank-id>
      <name>Mitoxantrone</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mitoxantrone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01206</drugbank-id>
      <name>Lomustine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lomustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01222</drugbank-id>
      <name>Budesonide</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Budesonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01229</drugbank-id>
      <name>Paclitaxel</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Paclitaxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01234</drugbank-id>
      <name>Dexamethasone</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01248</drugbank-id>
      <name>Docetaxel</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Docetaxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01254</drugbank-id>
      <name>Dasatinib</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dasatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01257</drugbank-id>
      <name>Eculizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Eculizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01262</drugbank-id>
      <name>Decitabine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Decitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01268</drugbank-id>
      <name>Sunitinib</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sunitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01280</drugbank-id>
      <name>Nelarabine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Nelarabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01281</drugbank-id>
      <name>Abatacept</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Abatacept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01285</drugbank-id>
      <name>Corticotropin</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Corticotropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01380</drugbank-id>
      <name>Cortisone acetate</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cortisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01384</drugbank-id>
      <name>Paramethasone</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Paramethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01394</drugbank-id>
      <name>Colchicine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Colchicine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01410</drugbank-id>
      <name>Ciclesonide</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ciclesonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01423</drugbank-id>
      <name>Stepronin</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Stepronin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01590</drugbank-id>
      <name>Everolimus</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Everolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01611</drugbank-id>
      <name>Hydroxychloroquine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Hydroxychloroquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01816</drugbank-id>
      <name>Castanospermine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Castanospermine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02546</drugbank-id>
      <name>Vorinostat</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vorinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02806</drugbank-id>
      <name>2-Methoxyethanol</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with 2-Methoxyethanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03523</drugbank-id>
      <name>Brequinar</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Brequinar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04572</drugbank-id>
      <name>Thiotepa</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Thiotepa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04630</drugbank-id>
      <name>Aldosterone</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Aldosterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04845</drugbank-id>
      <name>Ixabepilone</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ixabepilone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04868</drugbank-id>
      <name>Nilotinib</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Nilotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04951</drugbank-id>
      <name>Pirfenidone</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pirfenidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04956</drugbank-id>
      <name>Afelimomab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Afelimomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05015</drugbank-id>
      <name>Belinostat</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Belinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05109</drugbank-id>
      <name>Trabectedin</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Trabectedin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05258</drugbank-id>
      <name>Interferon alfa</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Interferon alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05259</drugbank-id>
      <name>Glatiramer</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Glatiramer.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05260</drugbank-id>
      <name>Gallium nitrate</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Gallium nitrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05459</drugbank-id>
      <name>Briakinumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Briakinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05472</drugbank-id>
      <name>Human interferon omega-1</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Human interferon omega-1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05676</drugbank-id>
      <name>Apremilast</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Apremilast.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05773</drugbank-id>
      <name>Trastuzumab emtansine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Trastuzumab emtansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06168</drugbank-id>
      <name>Canakinumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Canakinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06273</drugbank-id>
      <name>Tocilizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tocilizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06287</drugbank-id>
      <name>Temsirolimus</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Temsirolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06372</drugbank-id>
      <name>Rilonacept</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Rilonacept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06589</drugbank-id>
      <name>Pazopanib</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pazopanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06603</drugbank-id>
      <name>Panobinostat</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Panobinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06612</drugbank-id>
      <name>Mepolizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mepolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06616</drugbank-id>
      <name>Bosutinib</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bosutinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06662</drugbank-id>
      <name>Abetimus</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Abetimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06674</drugbank-id>
      <name>Golimumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Golimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06681</drugbank-id>
      <name>Belatacept</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Belatacept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06769</drugbank-id>
      <name>Bendamustine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bendamustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06772</drugbank-id>
      <name>Cabazitaxel</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cabazitaxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06813</drugbank-id>
      <name>Pralatrexate</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pralatrexate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08059</drugbank-id>
      <name>Wortmannin</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Wortmannin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08870</drugbank-id>
      <name>Brentuximab vedotin</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Brentuximab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08871</drugbank-id>
      <name>Eribulin</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Eribulin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08877</drugbank-id>
      <name>Ruxolitinib</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ruxolitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08879</drugbank-id>
      <name>Belimumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Belimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08880</drugbank-id>
      <name>Teriflunomide</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Teriflunomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08889</drugbank-id>
      <name>Carfilzomib</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Carfilzomib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08901</drugbank-id>
      <name>Ponatinib</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ponatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08904</drugbank-id>
      <name>Certolizumab pegol</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Certolizumab pegol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08906</drugbank-id>
      <name>Fluticasone furoate</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluticasone furoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08908</drugbank-id>
      <name>Dimethyl fumarate</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dimethyl fumarate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08910</drugbank-id>
      <name>Pomalidomide</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pomalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08935</drugbank-id>
      <name>Obinutuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Obinutuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08970</drugbank-id>
      <name>Fluprednidene</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluprednidene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09029</drugbank-id>
      <name>Secukinumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Secukinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09033</drugbank-id>
      <name>Vedolizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vedolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09036</drugbank-id>
      <name>Siltuximab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Siltuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09052</drugbank-id>
      <name>Blinatumomab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Blinatumomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09053</drugbank-id>
      <name>Ibrutinib</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ibrutinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09054</drugbank-id>
      <name>Idelalisib</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Idelalisib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09073</drugbank-id>
      <name>Palbociclib</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Palbociclib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09074</drugbank-id>
      <name>Olaparib</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Olaparib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09077</drugbank-id>
      <name>Dinutuximab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dinutuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09082</drugbank-id>
      <name>Vilanterol</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vilanterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09091</drugbank-id>
      <name>Tixocortol</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tixocortol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09122</drugbank-id>
      <name>Peginterferon beta-1a</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Peginterferon beta-1a.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09312</drugbank-id>
      <name>Antilymphocyte immunoglobulin (horse)</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Antilymphocyte immunoglobulin (horse).</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09378</drugbank-id>
      <name>Fluprednisolone</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluprednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09383</drugbank-id>
      <name>Meprednisone</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Meprednisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11466</drugbank-id>
      <name>Tepoxalin</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tepoxalin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11487</drugbank-id>
      <name>Dexamethasone isonicotinate</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dexamethasone isonicotinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11529</drugbank-id>
      <name>Melengestrol</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Melengestrol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11569</drugbank-id>
      <name>Ixekizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ixekizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11580</drugbank-id>
      <name>Ravulizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ravulizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11616</drugbank-id>
      <name>Pirarubicin</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pirarubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11693</drugbank-id>
      <name>Voclosporin</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Voclosporin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11708</drugbank-id>
      <name>Peficitinib</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Peficitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11767</drugbank-id>
      <name>Sarilumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sarilumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11776</drugbank-id>
      <name>Brodalumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Brodalumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11803</drugbank-id>
      <name>Sirukumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sirukumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11817</drugbank-id>
      <name>Baricitinib</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Baricitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11834</drugbank-id>
      <name>Guselkumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Guselkumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11921</drugbank-id>
      <name>Deflazacort</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Deflazacort.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12025</drugbank-id>
      <name>Triptolide</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Triptolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12371</drugbank-id>
      <name>Siponimod</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Siponimod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12612</drugbank-id>
      <name>Ozanimod</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ozanimod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12617</drugbank-id>
      <name>Mizoribine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mizoribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12692</drugbank-id>
      <name>Gusperimus</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Gusperimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12814</drugbank-id>
      <name>Cepeginterferon alfa-2B</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cepeginterferon alfa-2B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12902</drugbank-id>
      <name>Trofosfamide</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Trofosfamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12947</drugbank-id>
      <name>Doxifluridine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Doxifluridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12991</drugbank-id>
      <name>Deoxyspergualin</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Deoxyspergualin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12996</drugbank-id>
      <name>Acteoside</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Acteoside.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13003</drugbank-id>
      <name>Cortivazol</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cortivazol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13014</drugbank-id>
      <name>Hypericin</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Hypericin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13068</drugbank-id>
      <name>9-(N-methyl-L-isoleucine)-cyclosporin A</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13208</drugbank-id>
      <name>Prednylidene</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Prednylidene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13223</drugbank-id>
      <name>Fluocortin</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluocortin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13241</drugbank-id>
      <name>Begelomab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Begelomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13491</drugbank-id>
      <name>Fluperolone</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluperolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13843</drugbank-id>
      <name>Cloprednol</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cloprednol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13856</drugbank-id>
      <name>Fluclorolone</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluclorolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13867</drugbank-id>
      <name>Fluticasone</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluticasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14066</drugbank-id>
      <name>Tetrandrine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tetrandrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14219</drugbank-id>
      <name>Monomethyl fumarate</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Monomethyl fumarate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14512</drugbank-id>
      <name>Mometasone furoate</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mometasone furoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14539</drugbank-id>
      <name>Hydrocortisone acetate</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Hydrocortisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14545</drugbank-id>
      <name>Hydrocortisone succinate</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Hydrocortisone succinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14724</drugbank-id>
      <name>Emapalumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Emapalumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14762</drugbank-id>
      <name>Risankizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Risankizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14919</drugbank-id>
      <name>Rozanolixizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Rozanolixizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15253</drugbank-id>
      <name>Bleselumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bleselumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01013</drugbank-id>
      <name>Clobetasol propionate</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Clobetasol propionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01047</drugbank-id>
      <name>Fluocinonide</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluocinonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14540</drugbank-id>
      <name>Hydrocortisone butyrate</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Hydrocortisone butyrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00547</drugbank-id>
      <name>Desoximetasone</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Desoximetasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00764</drugbank-id>
      <name>Mometasone</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mometasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08971</drugbank-id>
      <name>Fluocortolone</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluocortolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11750</drugbank-id>
      <name>Clobetasol</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Clobetasol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00324</drugbank-id>
      <name>Fluorometholone</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluorometholone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09095</drugbank-id>
      <name>Difluocortolone</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Difluocortolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00108</drugbank-id>
      <name>Natalizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Natalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00337</drugbank-id>
      <name>Pimecrolimus</name>
      <description>The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01656</drugbank-id>
      <name>Roflumilast</name>
      <description>Roflumilast may increase the immunosuppressive activities of Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06688</drugbank-id>
      <name>Sipuleucel-T</name>
      <description>The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>The risk or severity of neutropenia can be increased when Ibritumomab tiuxetan is combined with Clozapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00054</drugbank-id>
      <name>Abciximab</name>
      <description>The risk or severity of adverse effects can be increased when Abciximab is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00063</drugbank-id>
      <name>Eptifibatide</name>
      <description>The risk or severity of adverse effects can be increased when Eptifibatide is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00208</drugbank-id>
      <name>Ticlopidine</name>
      <description>The risk or severity of adverse effects can be increased when Ticlopidine is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00261</drugbank-id>
      <name>Anagrelide</name>
      <description>The risk or severity of adverse effects can be increased when Anagrelide is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00758</drugbank-id>
      <name>Clopidogrel</name>
      <description>The risk or severity of adverse effects can be increased when Clopidogrel is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00775</drugbank-id>
      <name>Tirofiban</name>
      <description>The risk or severity of adverse effects can be increased when Tirofiban is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00806</drugbank-id>
      <name>Pentoxifylline</name>
      <description>The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00975</drugbank-id>
      <name>Dipyridamole</name>
      <description>The risk or severity of adverse effects can be increased when Dipyridamole is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01088</drugbank-id>
      <name>Iloprost</name>
      <description>The risk or severity of adverse effects can be increased when Iloprost is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01138</drugbank-id>
      <name>Sulfinpyrazone</name>
      <description>The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01166</drugbank-id>
      <name>Cilostazol</name>
      <description>The risk or severity of adverse effects can be increased when Cilostazol is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01207</drugbank-id>
      <name>Ridogrel</name>
      <description>The risk or severity of adverse effects can be increased when Ridogrel is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01236</drugbank-id>
      <name>Sevoflurane</name>
      <description>The risk or severity of adverse effects can be increased when Sevoflurane is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01240</drugbank-id>
      <name>Epoprostenol</name>
      <description>The risk or severity of adverse effects can be increased when Epoprostenol is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02709</drugbank-id>
      <name>Resveratrol</name>
      <description>The risk or severity of adverse effects can be increased when Resveratrol is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04743</drugbank-id>
      <name>Nimesulide</name>
      <description>The risk or severity of adverse effects can be increased when Nimesulide is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04905</drugbank-id>
      <name>Tesmilifene</name>
      <description>The risk or severity of adverse effects can be increased when Tesmilifene is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04932</drugbank-id>
      <name>Defibrotide</name>
      <description>The risk or severity of adverse effects can be increased when Defibrotide is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05229</drugbank-id>
      <name>Beraprost</name>
      <description>The risk or severity of adverse effects can be increased when Beraprost is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05266</drugbank-id>
      <name>Ibudilast</name>
      <description>The risk or severity of adverse effects can be increased when Ibudilast is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05767</drugbank-id>
      <name>Andrographolide</name>
      <description>The risk or severity of adverse effects can be increased when Andrographolide is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06081</drugbank-id>
      <name>Caplacizumab</name>
      <description>The risk or severity of adverse effects can be increased when Caplacizumab is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06209</drugbank-id>
      <name>Prasugrel</name>
      <description>The risk or severity of adverse effects can be increased when Prasugrel is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06441</drugbank-id>
      <name>Cangrelor</name>
      <description>The risk or severity of adverse effects can be increased when Cangrelor is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07615</drugbank-id>
      <name>Tranilast</name>
      <description>The risk or severity of adverse effects can be increased when Tranilast is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08814</drugbank-id>
      <name>Triflusal</name>
      <description>The risk or severity of adverse effects can be increased when Triflusal is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08816</drugbank-id>
      <name>Ticagrelor</name>
      <description>The risk or severity of adverse effects can be increased when Ticagrelor is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08887</drugbank-id>
      <name>Icosapent ethyl</name>
      <description>The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09030</drugbank-id>
      <name>Vorapaxar</name>
      <description>The risk or severity of adverse effects can be increased when Vorapaxar is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09283</drugbank-id>
      <name>Trapidil</name>
      <description>The risk or severity of adverse effects can be increased when Trapidil is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12092</drugbank-id>
      <name>Naftopidil</name>
      <description>The risk or severity of adverse effects can be increased when Naftopidil is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12163</drugbank-id>
      <name>Sarpogrelate</name>
      <description>The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12321</drugbank-id>
      <name>Ifetroban</name>
      <description>The risk or severity of adverse effects can be increased when Ifetroban is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12445</drugbank-id>
      <name>Nitroaspirin</name>
      <description>The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12465</drugbank-id>
      <name>Ketanserin</name>
      <description>The risk or severity of adverse effects can be increased when Ketanserin is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12545</drugbank-id>
      <name>Indobufen</name>
      <description>The risk or severity of adverse effects can be increased when Indobufen is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12749</drugbank-id>
      <name>Butylphthalide</name>
      <description>The risk or severity of adverse effects can be increased when Butylphthalide is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12771</drugbank-id>
      <name>Hydroxytyrosol</name>
      <description>The risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13036</drugbank-id>
      <name>Ramatroban</name>
      <description>The risk or severity of adverse effects can be increased when Ramatroban is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13327</drugbank-id>
      <name>Picotamide</name>
      <description>The risk or severity of adverse effects can be increased when Picotamide is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13367</drugbank-id>
      <name>Cloricromen</name>
      <description>The risk or severity of adverse effects can be increased when Cloricromen is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13400</drugbank-id>
      <name>Linsidomine</name>
      <description>The risk or severity of adverse effects can be increased when Linsidomine is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13510</drugbank-id>
      <name>Buflomedil</name>
      <description>The risk or severity of adverse effects can be increased when Buflomedil is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13929</drugbank-id>
      <name>Relcovaptan</name>
      <description>The risk or severity of adverse effects can be increased when Relcovaptan is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01015</drugbank-id>
      <name>Sulfamethoxazole</name>
      <description>The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00255</drugbank-id>
      <name>Diethylstilbestrol</name>
      <description>Diethylstilbestrol may increase the thrombogenic activities of Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00269</drugbank-id>
      <name>Chlorotrianisene</name>
      <description>Chlorotrianisene may increase the thrombogenic activities of Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00286</drugbank-id>
      <name>Conjugated estrogens</name>
      <description>Conjugated estrogens may increase the thrombogenic activities of Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00655</drugbank-id>
      <name>Estrone</name>
      <description>Estrone may increase the thrombogenic activities of Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00783</drugbank-id>
      <name>Estradiol</name>
      <description>Estradiol may increase the thrombogenic activities of Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00890</drugbank-id>
      <name>Dienestrol</name>
      <description>Dienestrol may increase the thrombogenic activities of Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00977</drugbank-id>
      <name>Ethinylestradiol</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01357</drugbank-id>
      <name>Mestranol</name>
      <description>Mestranol may increase the thrombogenic activities of Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04573</drugbank-id>
      <name>Estriol</name>
      <description>Estriol may increase the thrombogenic activities of Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04574</drugbank-id>
      <name>Estrone sulfate</name>
      <description>Estrone sulfate may increase the thrombogenic activities of Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04575</drugbank-id>
      <name>Quinestrol</name>
      <description>Quinestrol may increase the thrombogenic activities of Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07931</drugbank-id>
      <name>Hexestrol</name>
      <description>Hexestrol may increase the thrombogenic activities of Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09070</drugbank-id>
      <name>Tibolone</name>
      <description>Tibolone may increase the thrombogenic activities of Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09317</drugbank-id>
      <name>Synthetic Conjugated Estrogens, A</name>
      <description>Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09318</drugbank-id>
      <name>Synthetic Conjugated Estrogens, B</name>
      <description>Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09369</drugbank-id>
      <name>Polyestradiol phosphate</name>
      <description>Polyestradiol phosphate may increase the thrombogenic activities of Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09381</drugbank-id>
      <name>Esterified estrogens</name>
      <description>Esterified estrogens may increase the thrombogenic activities of Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11478</drugbank-id>
      <name>Zeranol</name>
      <description>Zeranol may increase the thrombogenic activities of Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11674</drugbank-id>
      <name>Equol</name>
      <description>Equol may increase the thrombogenic activities of Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12487</drugbank-id>
      <name>Promestriene</name>
      <description>Promestriene may increase the thrombogenic activities of Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13143</drugbank-id>
      <name>Methallenestril</name>
      <description>Methallenestril may increase the thrombogenic activities of Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13386</drugbank-id>
      <name>Epimestrol</name>
      <description>Epimestrol may increase the thrombogenic activities of Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13418</drugbank-id>
      <name>Moxestrol</name>
      <description>Moxestrol may increase the thrombogenic activities of Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13952</drugbank-id>
      <name>Estradiol acetate</name>
      <description>Estradiol acetate may increase the thrombogenic activities of Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13953</drugbank-id>
      <name>Estradiol benzoate</name>
      <description>Estradiol benzoate may increase the thrombogenic activities of Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13954</drugbank-id>
      <name>Estradiol cypionate</name>
      <description>Estradiol cypionate may increase the thrombogenic activities of Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13956</drugbank-id>
      <name>Estradiol valerate</name>
      <description>Estradiol valerate may increase the thrombogenic activities of Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15334</drugbank-id>
      <name>Biochanin A</name>
      <description>Biochanin A may increase the thrombogenic activities of Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15335</drugbank-id>
      <name>Formononetin</name>
      <description>Formononetin may increase the thrombogenic activities of Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01097</drugbank-id>
      <name>Leflunomide</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Leflunomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08895</drugbank-id>
      <name>Tofacitinib</name>
      <description>Ibritumomab tiuxetan may increase the immunosuppressive activities of Tofacitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00072</drugbank-id>
      <name>Trastuzumab</name>
      <description>Trastuzumab may increase the neutropenic activities of Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08868</drugbank-id>
      <name>Fingolimod</name>
      <description>Ibritumomab tiuxetan may increase the immunosuppressive activities of Fingolimod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00864</drugbank-id>
      <name>Tacrolimus</name>
      <description>Tacrolimus may increase the immunosuppressive activities of Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04914</drugbank-id>
      <name>G17DT</name>
      <description>The therapeutic efficacy of G17DT can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05144</drugbank-id>
      <name>PEV3A</name>
      <description>The therapeutic efficacy of PEV3A can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05325</drugbank-id>
      <name>INGN 225</name>
      <description>The therapeutic efficacy of INGN 225 can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05374</drugbank-id>
      <name>Rindopepimut</name>
      <description>The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05440</drugbank-id>
      <name>SRP 299</name>
      <description>The therapeutic efficacy of SRP 299 can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05942</drugbank-id>
      <name>GI-5005</name>
      <description>The therapeutic efficacy of GI-5005 can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06400</drugbank-id>
      <name>Vitespen</name>
      <description>The therapeutic efficacy of Vitespen can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06584</drugbank-id>
      <name>TG4010</name>
      <description>The therapeutic efficacy of TG4010 can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09057</drugbank-id>
      <name>Anthrax immune globulin human</name>
      <description>The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10062</drugbank-id>
      <name>Rabies virus inactivated antigen, B</name>
      <description>The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10076</drugbank-id>
      <name>Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen</name>
      <description>The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10276</drugbank-id>
      <name>Rotavirus vaccine</name>
      <description>The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10283</drugbank-id>
      <name>Rabies virus inactivated antigen, A</name>
      <description>The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10342</drugbank-id>
      <name>Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen</name>
      <description>The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10583</drugbank-id>
      <name>Clostridium tetani toxoid antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10584</drugbank-id>
      <name>Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10600</drugbank-id>
      <name>Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10769</drugbank-id>
      <name>Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10794</drugbank-id>
      <name>Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10803</drugbank-id>
      <name>Typhoid Vi polysaccharide vaccine</name>
      <description>The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10989</drugbank-id>
      <name>Hepatitis A Vaccine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10990</drugbank-id>
      <name>Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen</name>
      <description>The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11038</drugbank-id>
      <name>Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11040</drugbank-id>
      <name>Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11041</drugbank-id>
      <name>Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11044</drugbank-id>
      <name>Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11603</drugbank-id>
      <name>Human rabies virus immune globulin</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11627</drugbank-id>
      <name>Hepatitis B Vaccine (Recombinant)</name>
      <description>The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12568</drugbank-id>
      <name>Tecemotide</name>
      <description>The therapeutic efficacy of Tecemotide can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14022</drugbank-id>
      <name>Typhoid vaccine</name>
      <description>The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14384</drugbank-id>
      <name>Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14385</drugbank-id>
      <name>Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14394</drugbank-id>
      <name>Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen</name>
      <description>The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14445</drugbank-id>
      <name>Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14449</drugbank-id>
      <name>Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen</name>
      <description>The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14619</drugbank-id>
      <name>Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14620</drugbank-id>
      <name>Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14711</drugbank-id>
      <name>Smallpox (Vaccinia) Vaccine, Live</name>
      <description>The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15274</drugbank-id>
      <name>Pertussis vaccine</name>
      <description>The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15461</drugbank-id>
      <name>Yersinia pestis 195/p antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13924</drugbank-id>
      <name>Varicella Zoster Vaccine (Recombinant)</name>
      <description>The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15483</drugbank-id>
      <name>Modified vaccinia ankara</name>
      <description>The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15654</drugbank-id>
      <name>Moderna COVID-19 Vaccine</name>
      <description>The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00266</drugbank-id>
      <name>Dicoumarol</name>
      <description>The risk or severity of adverse effects can be increased when Dicoumarol is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00407</drugbank-id>
      <name>Ardeparin</name>
      <description>The risk or severity of adverse effects can be increased when Ardeparin is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00498</drugbank-id>
      <name>Phenindione</name>
      <description>The risk or severity of adverse effects can be increased when Phenindione is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>The risk or severity of adverse effects can be increased when Warfarin is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00686</drugbank-id>
      <name>Pentosan polysulfate</name>
      <description>The risk or severity of adverse effects can be increased when Pentosan polysulfate is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00946</drugbank-id>
      <name>Phenprocoumon</name>
      <description>The risk or severity of adverse effects can be increased when Phenprocoumon is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>The risk or severity of adverse effects can be increased when Acenocoumarol is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03410</drugbank-id>
      <name>4-hydroxycoumarin</name>
      <description>The risk or severity of adverse effects can be increased when 4-hydroxycoumarin is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04665</drugbank-id>
      <name>Coumarin</name>
      <description>The risk or severity of adverse effects can be increased when Coumarin is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04898</drugbank-id>
      <name>Ximelagatran</name>
      <description>The risk or severity of adverse effects can be increased when Ximelagatran is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04925</drugbank-id>
      <name>Desmoteplase</name>
      <description>The risk or severity of adverse effects can be increased when Desmoteplase is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05254</drugbank-id>
      <name>Fibrinolysin</name>
      <description>The risk or severity of adverse effects can be increased when Fibrinolysin is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06228</drugbank-id>
      <name>Rivaroxaban</name>
      <description>The risk or severity of adverse effects can be increased when Rivaroxaban is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06271</drugbank-id>
      <name>Sulodexide</name>
      <description>The risk or severity of adverse effects can be increased when Sulodexide is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06294</drugbank-id>
      <name>Semuloparin</name>
      <description>The risk or severity of adverse effects can be increased when Semuloparin is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06406</drugbank-id>
      <name>Idraparinux</name>
      <description>The risk or severity of adverse effects can be increased when Idraparinux is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06543</drugbank-id>
      <name>Astaxanthin</name>
      <description>The risk or severity of adverse effects can be increased when Astaxanthin is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06605</drugbank-id>
      <name>Apixaban</name>
      <description>The risk or severity of adverse effects can be increased when Apixaban is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06635</drugbank-id>
      <name>Otamixaban</name>
      <description>The risk or severity of adverse effects can be increased when Otamixaban is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06679</drugbank-id>
      <name>Amediplase</name>
      <description>The risk or severity of adverse effects can be increased when Amediplase is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06695</drugbank-id>
      <name>Dabigatran etexilate</name>
      <description>The risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07767</drugbank-id>
      <name>Ferulic acid</name>
      <description>The risk or severity of adverse effects can be increased when Ferulic acid is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08496</drugbank-id>
      <name>(R)-warfarin</name>
      <description>The risk or severity of adverse effects can be increased when (R)-warfarin is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08794</drugbank-id>
      <name>Ethyl biscoumacetate</name>
      <description>The risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08994</drugbank-id>
      <name>Ditazole</name>
      <description>The risk or severity of adverse effects can be increased when Ditazole is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09075</drugbank-id>
      <name>Edoxaban</name>
      <description>The risk or severity of adverse effects can be increased when Edoxaban is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09125</drugbank-id>
      <name>Potassium citrate</name>
      <description>The risk or severity of adverse effects can be increased when Potassium citrate is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09154</drugbank-id>
      <name>Sodium citrate</name>
      <description>The risk or severity of adverse effects can be increased when Sodium citrate is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11154</drugbank-id>
      <name>Zinc citrate</name>
      <description>The risk or severity of adverse effects can be increased when Zinc citrate is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11984</drugbank-id>
      <name>Letaxaban</name>
      <description>The risk or severity of adverse effects can be increased when Letaxaban is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12289</drugbank-id>
      <name>Darexaban</name>
      <description>The risk or severity of adverse effects can be increased when Darexaban is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12364</drugbank-id>
      <name>Betrixaban</name>
      <description>The risk or severity of adverse effects can be increased when Betrixaban is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12598</drugbank-id>
      <name>Nafamostat</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12726</drugbank-id>
      <name>Monteplase</name>
      <description>The risk or severity of adverse effects can be increased when Monteplase is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13136</drugbank-id>
      <name>Fluindione</name>
      <description>The risk or severity of adverse effects can be increased when Fluindione is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13199</drugbank-id>
      <name>Brinase</name>
      <description>The risk or severity of adverse effects can be increased when Brinase is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13275</drugbank-id>
      <name>Clorindione</name>
      <description>The risk or severity of adverse effects can be increased when Clorindione is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13347</drugbank-id>
      <name>Diphenadione</name>
      <description>The risk or severity of adverse effects can be increased when Diphenadione is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13451</drugbank-id>
      <name>Tioclomarol</name>
      <description>The risk or severity of adverse effects can be increased when Tioclomarol is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13616</drugbank-id>
      <name>Melagatran</name>
      <description>The risk or severity of adverse effects can be increased when Melagatran is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13646</drugbank-id>
      <name>Saruplase</name>
      <description>The risk or severity of adverse effects can be increased when Saruplase is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14055</drugbank-id>
      <name>(S)-Warfarin</name>
      <description>The risk or severity of adverse effects can be increased when (S)-Warfarin is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14094</drugbank-id>
      <name>Tocopherylquinone</name>
      <description>The risk or severity of adverse effects can be increased when Tocopherylquinone is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14726</drugbank-id>
      <name>Dabigatran</name>
      <description>The risk or severity of adverse effects can be increased when Dabigatran is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01109</drugbank-id>
      <name>Heparin</name>
      <description>The risk or severity of adverse effects can be increased when Heparin is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06754</drugbank-id>
      <name>Danaparoid</name>
      <description>The risk or severity of adverse effects can be increased when Danaparoid is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13124</drugbank-id>
      <name>Troxerutin</name>
      <description>The risk or severity of adverse effects can be increased when Troxerutin is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11988</drugbank-id>
      <name>Ocrelizumab</name>
      <description>Ocrelizumab may increase the immunosuppressive activities of Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13200</drugbank-id>
      <name>Lipegfilgrastim</name>
      <description>Ibritumomab tiuxetan may increase the myelosuppressive activities of Lipegfilgrastim.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10317</drugbank-id>
      <name>Rubella virus vaccine</name>
      <description>The risk or severity of infection can be increased when Rubella virus vaccine is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10318</drugbank-id>
      <name>Varicella Zoster Vaccine (Live/attenuated)</name>
      <description>The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10343</drugbank-id>
      <name>Bacillus calmette-guerin substrain tice live antigen</name>
      <description>The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10804</drugbank-id>
      <name>Bacillus calmette-guerin substrain connaught live antigen</name>
      <description>The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10805</drugbank-id>
      <name>Yellow Fever Vaccine</name>
      <description>The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11003</drugbank-id>
      <name>Anthrax vaccine</name>
      <description>The risk or severity of infection can be increased when Anthrax vaccine is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11050</drugbank-id>
      <name>Typhoid Vaccine Live</name>
      <description>The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12386</drugbank-id>
      <name>Bacillus calmette-guerin substrain danish 1331 live antigen</name>
      <description>The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12768</drugbank-id>
      <name>BCG vaccine</name>
      <description>The risk or severity of infection can be increased when BCG vaccine is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14409</drugbank-id>
      <name>Human adenovirus e serotype 4 strain cl-68578 antigen</name>
      <description>The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14443</drugbank-id>
      <name>Vibrio cholerae CVD 103-HgR strain live antigen</name>
      <description>The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14685</drugbank-id>
      <name>Adenovirus type 7 vaccine live</name>
      <description>The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00002</drugbank-id>
      <name>Cetuximab</name>
      <description>The risk or severity of adverse effects can be increased when Cetuximab is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00028</drugbank-id>
      <name>Human immunoglobulin G</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00043</drugbank-id>
      <name>Omalizumab</name>
      <description>The risk or severity of adverse effects can be increased when Omalizumab is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00057</drugbank-id>
      <name>Indium In-111 satumomab pendetide</name>
      <description>The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00076</drugbank-id>
      <name>Digoxin Immune Fab (Ovine)</name>
      <description>The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00089</drugbank-id>
      <name>Capromab pendetide</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Capromab pendetide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00110</drugbank-id>
      <name>Palivizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Palivizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00113</drugbank-id>
      <name>Technetium Tc-99m arcitumomab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Technetium Tc-99m arcitumomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01269</drugbank-id>
      <name>Panitumumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Panitumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01270</drugbank-id>
      <name>Ranibizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ranibizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04901</drugbank-id>
      <name>Galiximab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Galiximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04949</drugbank-id>
      <name>Pexelizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pexelizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04958</drugbank-id>
      <name>Epratuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Epratuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04962</drugbank-id>
      <name>Bectumomab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bectumomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04964</drugbank-id>
      <name>Oregovomab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04988</drugbank-id>
      <name>IGN311</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with IGN311.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05006</drugbank-id>
      <name>Adecatumumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Adecatumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05097</drugbank-id>
      <name>Labetuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Labetuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05101</drugbank-id>
      <name>Matuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Matuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05111</drugbank-id>
      <name>Fontolizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fontolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05136</drugbank-id>
      <name>Bavituximab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bavituximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05139</drugbank-id>
      <name>CR002</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with CR002.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05209</drugbank-id>
      <name>Rozrolimupab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Rozrolimupab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05304</drugbank-id>
      <name>Girentuximab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Girentuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05336</drugbank-id>
      <name>Obiltoxaximab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Obiltoxaximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05405</drugbank-id>
      <name>XTL-001</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with XTL-001.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05437</drugbank-id>
      <name>NAV 1800</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with NAV 1800.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05496</drugbank-id>
      <name>Otelixizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Otelixizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05545</drugbank-id>
      <name>AMG 108</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with AMG 108.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05550</drugbank-id>
      <name>Iratumumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Iratumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05555</drugbank-id>
      <name>Enokizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Enokizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05578</drugbank-id>
      <name>Ramucirumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ramucirumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05595</drugbank-id>
      <name>Farletuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Farletuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05656</drugbank-id>
      <name>Veltuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Veltuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05793</drugbank-id>
      <name>PRO-542</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with PRO-542.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05797</drugbank-id>
      <name>TNX-901</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with TNX-901.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05889</drugbank-id>
      <name>Inotuzumab ozogamicin</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Inotuzumab ozogamicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05892</drugbank-id>
      <name>RI 624</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with RI 624.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05915</drugbank-id>
      <name>MYO-029</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with MYO-029.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05916</drugbank-id>
      <name>CT-011</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with CT-011.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05941</drugbank-id>
      <name>Leronlimab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Leronlimab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05996</drugbank-id>
      <name>Glembatumumab vedotin</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Glembatumumab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06043</drugbank-id>
      <name>Olaratumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Olaratumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06049</drugbank-id>
      <name>IPH 2101</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with IPH 2101.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06050</drugbank-id>
      <name>TB-402</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with TB-402.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06101</drugbank-id>
      <name>IMC-1C11</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with IMC-1C11.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06116</drugbank-id>
      <name>Eldelumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Eldelumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06162</drugbank-id>
      <name>Lumiliximab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lumiliximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06186</drugbank-id>
      <name>Ipilimumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ipilimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06192</drugbank-id>
      <name>Nimotuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Nimotuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06241</drugbank-id>
      <name>Clenoliximab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Clenoliximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06304</drugbank-id>
      <name>BIIB015</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with BIIB015.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06305</drugbank-id>
      <name>Sonepcizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sonepcizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06310</drugbank-id>
      <name>Motavizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Motavizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06317</drugbank-id>
      <name>Elotuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Elotuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06318</drugbank-id>
      <name>AVE9633</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with AVE9633.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06322</drugbank-id>
      <name>Carotuximab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Carotuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06324</drugbank-id>
      <name>XmAb 2513</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with XmAb 2513.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06342</drugbank-id>
      <name>Coltuximab ravtansine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Coltuximab ravtansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06343</drugbank-id>
      <name>Teprotumumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Teprotumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06360</drugbank-id>
      <name>Lucatumumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lucatumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06366</drugbank-id>
      <name>Pertuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pertuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06371</drugbank-id>
      <name>Siplizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Siplizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06467</drugbank-id>
      <name>Apolizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Apolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06474</drugbank-id>
      <name>Sibrotuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sibrotuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06550</drugbank-id>
      <name>Bivatuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bivatuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06557</drugbank-id>
      <name>Lerdelimumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lerdelimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06599</drugbank-id>
      <name>Lexatumumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lexatumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06602</drugbank-id>
      <name>Reslizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Reslizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06606</drugbank-id>
      <name>Teplizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Teplizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06607</drugbank-id>
      <name>Catumaxomab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Catumaxomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06647</drugbank-id>
      <name>Volociximab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Volociximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06650</drugbank-id>
      <name>Ofatumumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ofatumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08902</drugbank-id>
      <name>Raxibacumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Raxibacumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09035</drugbank-id>
      <name>Nivolumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Nivolumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09037</drugbank-id>
      <name>Pembrolizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pembrolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09045</drugbank-id>
      <name>Dulaglutide</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dulaglutide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09105</drugbank-id>
      <name>Asfotase alfa</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Asfotase alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09264</drugbank-id>
      <name>Idarucizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Idarucizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09302</drugbank-id>
      <name>Alirocumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Alirocumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09303</drugbank-id>
      <name>Evolocumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Evolocumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09331</drugbank-id>
      <name>Daratumumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Daratumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09559</drugbank-id>
      <name>Necitumumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Necitumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11595</drugbank-id>
      <name>Atezolizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Atezolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11604</drugbank-id>
      <name>Tetanus Immune Globulin</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tetanus Immune Globulin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11608</drugbank-id>
      <name>Eftrenonacog alfa</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Eftrenonacog alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11621</drugbank-id>
      <name>Human Varicella-Zoster Immune Globulin</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Human Varicella-Zoster Immune Globulin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11646</drugbank-id>
      <name>Conatumumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Conatumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11657</drugbank-id>
      <name>Tabalumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tabalumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11680</drugbank-id>
      <name>Ficlatuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ficlatuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11685</drugbank-id>
      <name>Figitumumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Figitumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11714</drugbank-id>
      <name>Durvalumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Durvalumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11715</drugbank-id>
      <name>Bapineuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bapineuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11731</drugbank-id>
      <name>Depatuxizumab mafodotin</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Depatuxizumab mafodotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11746</drugbank-id>
      <name>Onartuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Onartuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11756</drugbank-id>
      <name>Solanezumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Solanezumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11771</drugbank-id>
      <name>Tremelimumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tremelimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11826</drugbank-id>
      <name>Lampalizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lampalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11840</drugbank-id>
      <name>Dalotuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dalotuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11849</drugbank-id>
      <name>Emibetuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Emibetuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11850</drugbank-id>
      <name>Ublituximab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ublituximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11856</drugbank-id>
      <name>Ligelizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ligelizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11857</drugbank-id>
      <name>Seribantumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Seribantumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11862</drugbank-id>
      <name>Landogrozumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Landogrozumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11866</drugbank-id>
      <name>Romosozumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Romosozumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11884</drugbank-id>
      <name>Vadastuximab Talirine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vadastuximab Talirine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11914</drugbank-id>
      <name>Lebrikizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lebrikizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11930</drugbank-id>
      <name>Varlilumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Varlilumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11945</drugbank-id>
      <name>Avelumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Avelumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11959</drugbank-id>
      <name>Crenezumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Crenezumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11972</drugbank-id>
      <name>Rilotumumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Rilotumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11976</drugbank-id>
      <name>Anifrolumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Anifrolumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12023</drugbank-id>
      <name>Benralizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Benralizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12034</drugbank-id>
      <name>Gantenerumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Gantenerumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12053</drugbank-id>
      <name>Visilizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Visilizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12077</drugbank-id>
      <name>Urelumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Urelumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12089</drugbank-id>
      <name>Lorvotuzumab mertansine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lorvotuzumab mertansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12090</drugbank-id>
      <name>Patritumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Patritumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12102</drugbank-id>
      <name>Fulranumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fulranumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12104</drugbank-id>
      <name>Tarextumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tarextumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12118</drugbank-id>
      <name>Sotatercept</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sotatercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12119</drugbank-id>
      <name>Gevokizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Gevokizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12142</drugbank-id>
      <name>Duligotuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Duligotuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12152</drugbank-id>
      <name>Simtuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Simtuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12157</drugbank-id>
      <name>Fasinumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fasinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12159</drugbank-id>
      <name>Dupilumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dupilumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12169</drugbank-id>
      <name>Tralokinumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tralokinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12189</drugbank-id>
      <name>Etrolizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Etrolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12202</drugbank-id>
      <name>Zalutumumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Zalutumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12205</drugbank-id>
      <name>Ganitumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ganitumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12213</drugbank-id>
      <name>Etaracizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Etaracizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12240</drugbank-id>
      <name>Polatuzumab vedotin</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Polatuzumab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12246</drugbank-id>
      <name>Inclacumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Inclacumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12250</drugbank-id>
      <name>Cixutumumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cixutumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12261</drugbank-id>
      <name>Ascrinvacumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ascrinvacumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12274</drugbank-id>
      <name>Aducanumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Aducanumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12281</drugbank-id>
      <name>Luspatercept</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Luspatercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12296</drugbank-id>
      <name>GS-5745</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with GS-5745.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12317</drugbank-id>
      <name>Vanucizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vanucizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12331</drugbank-id>
      <name>Labetuzumab govitecan</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Labetuzumab govitecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12335</drugbank-id>
      <name>Tanezumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tanezumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12342</drugbank-id>
      <name>Ensituximab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ensituximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12344</drugbank-id>
      <name>Fezakinumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fezakinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12363</drugbank-id>
      <name>Dusigitumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dusigitumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12396</drugbank-id>
      <name>Fresolimumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fresolimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12413</drugbank-id>
      <name>Indusatumab vedotin</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Indusatumab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12456</drugbank-id>
      <name>Bococizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bococizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12489</drugbank-id>
      <name>Mirvetuximab Soravtansine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mirvetuximab Soravtansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12498</drugbank-id>
      <name>Mogamulizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mogamulizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12520</drugbank-id>
      <name>Plozalizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Plozalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12534</drugbank-id>
      <name>Mavrilimumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mavrilimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12560</drugbank-id>
      <name>Blosozumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Blosozumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12584</drugbank-id>
      <name>Bimagrumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bimagrumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12589</drugbank-id>
      <name>Dacetuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dacetuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12609</drugbank-id>
      <name>Tovetumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tovetumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12683</drugbank-id>
      <name>Lumretuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lumretuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12698</drugbank-id>
      <name>Ibalizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ibalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12701</drugbank-id>
      <name>Intetumumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Intetumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12718</drugbank-id>
      <name>Carlumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Carlumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12734</drugbank-id>
      <name>Demcizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Demcizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12773</drugbank-id>
      <name>Sifalimumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sifalimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12775</drugbank-id>
      <name>Abituzumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Abituzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12797</drugbank-id>
      <name>Ecromeximab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ecromeximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12807</drugbank-id>
      <name>Naptumomab Estafenatox</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Naptumomab Estafenatox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12815</drugbank-id>
      <name>Crotedumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Crotedumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12820</drugbank-id>
      <name>Concizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Concizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12826</drugbank-id>
      <name>Depatuxizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Depatuxizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12844</drugbank-id>
      <name>Rontalizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Rontalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12845</drugbank-id>
      <name>Amatuximab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Amatuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12849</drugbank-id>
      <name>Clazakizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Clazakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12891</drugbank-id>
      <name>Ozanezumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ozanezumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12893</drugbank-id>
      <name>Sacituzumab govitecan</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sacituzumab govitecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12917</drugbank-id>
      <name>Bimekizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bimekizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12943</drugbank-id>
      <name>Milatuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Milatuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12976</drugbank-id>
      <name>Robatumumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Robatumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13017</drugbank-id>
      <name>Rovalpituzumab Tesirine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Rovalpituzumab Tesirine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13037</drugbank-id>
      <name>Namilumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Namilumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13045</drugbank-id>
      <name>Racotumomab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Racotumomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13073</drugbank-id>
      <name>Tregalizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tregalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13127</drugbank-id>
      <name>Olokizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Olokizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13140</drugbank-id>
      <name>Bezlotoxumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bezlotoxumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13375</drugbank-id>
      <name>Edrecolomab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Edrecolomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13535</drugbank-id>
      <name>Nebacumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Nebacumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13886</drugbank-id>
      <name>Human cytomegalovirus immune globulin</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Human cytomegalovirus immune globulin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13923</drugbank-id>
      <name>Emicizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Emicizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13976</drugbank-id>
      <name>Sulesomab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sulesomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13979</drugbank-id>
      <name>Besilesomab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Besilesomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14012</drugbank-id>
      <name>Burosumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Burosumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14039</drugbank-id>
      <name>Erenumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Erenumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14040</drugbank-id>
      <name>Eptinezumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Eptinezumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14041</drugbank-id>
      <name>Fremanezumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fremanezumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14042</drugbank-id>
      <name>Galcanezumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Galcanezumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14211</drugbank-id>
      <name>Fanolesomab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fanolesomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14580</drugbank-id>
      <name>Lecanemab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lecanemab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14597</drugbank-id>
      <name>Lanadelumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lanadelumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14707</drugbank-id>
      <name>Cemiplimab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cemiplimab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14776</drugbank-id>
      <name>Camrelizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Camrelizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14778</drugbank-id>
      <name>Setrusumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Setrusumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14784</drugbank-id>
      <name>Gancotamab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Gancotamab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14809</drugbank-id>
      <name>Anetumab ravtansine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Anetumab ravtansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14811</drugbank-id>
      <name>Isatuximab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Isatuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14824</drugbank-id>
      <name>Icrucumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Icrucumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14843</drugbank-id>
      <name>Codrituzumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Codrituzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14864</drugbank-id>
      <name>Brolucizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Brolucizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14871</drugbank-id>
      <name>Xentuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Xentuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14877</drugbank-id>
      <name>Lintuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lintuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14891</drugbank-id>
      <name>Vobarilizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vobarilizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14897</drugbank-id>
      <name>Parsatuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Parsatuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14905</drugbank-id>
      <name>Emactuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Emactuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14907</drugbank-id>
      <name>Bevacizumab zirconium Zr-89</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bevacizumab zirconium Zr-89.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14908</drugbank-id>
      <name>Refanezumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Refanezumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14947</drugbank-id>
      <name>Bermekimab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bermekimab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14952</drugbank-id>
      <name>Pamrevlumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pamrevlumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14959</drugbank-id>
      <name>Opicinumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Opicinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14962</drugbank-id>
      <name>Trastuzumab deruxtecan</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Trastuzumab deruxtecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14967</drugbank-id>
      <name>Margetuximab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Margetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14988</drugbank-id>
      <name>Dalantercept</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dalantercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14997</drugbank-id>
      <name>Pateclizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pateclizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15014</drugbank-id>
      <name>Gremubamab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Gremubamab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15022</drugbank-id>
      <name>Apomab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Apomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15044</drugbank-id>
      <name>Tafasitamab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tafasitamab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15045</drugbank-id>
      <name>Ipafricept</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ipafricept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15076</drugbank-id>
      <name>Abrilumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Abrilumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15089</drugbank-id>
      <name>Frovocimab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Frovocimab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15090</drugbank-id>
      <name>Tezepelumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tezepelumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15101</drugbank-id>
      <name>Tigatuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tigatuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15104</drugbank-id>
      <name>Telisotuzumab vedotin</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Telisotuzumab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15113</drugbank-id>
      <name>Utomilumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Utomilumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15118</drugbank-id>
      <name>Zolbetuximab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Zolbetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15135</drugbank-id>
      <name>Ponezumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ponezumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15160</drugbank-id>
      <name>Asunercept</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Asunercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15172</drugbank-id>
      <name>Suvratoxumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Suvratoxumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15225</drugbank-id>
      <name>Mitazalimab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mitazalimab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15252</drugbank-id>
      <name>Nemolizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Nemolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15277</drugbank-id>
      <name>Gedivumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Gedivumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15336</drugbank-id>
      <name>Valanafusp alfa</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Valanafusp alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15349</drugbank-id>
      <name>Sofituzumab vedotin</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sofituzumab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15354</drugbank-id>
      <name>Evinacumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Evinacumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15363</drugbank-id>
      <name>Istiratumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Istiratumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15383</drugbank-id>
      <name>Pidilizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pidilizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15397</drugbank-id>
      <name>GMA-161</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with GMA-161.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15409</drugbank-id>
      <name>Ladiratuzumab vedotin</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ladiratuzumab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15415</drugbank-id>
      <name>Tomaralimab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tomaralimab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15428</drugbank-id>
      <name>Vesencumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vesencumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15432</drugbank-id>
      <name>Pinatuzumab vedotin</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pinatuzumab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15441</drugbank-id>
      <name>Lulizumab pegol</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lulizumab pegol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15443</drugbank-id>
      <name>Lorukafusp alfa</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lorukafusp alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15453</drugbank-id>
      <name>Naratuximab emtansine</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Naratuximab emtansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14004</drugbank-id>
      <name>Tildrakizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05679</drugbank-id>
      <name>Ustekinumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ustekinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15559</drugbank-id>
      <name>Zenocutuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Zenocutuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15898</drugbank-id>
      <name>Atoltivimab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Atoltivimab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15899</drugbank-id>
      <name>Maftivimab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Maftivimab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15900</drugbank-id>
      <name>Odesivimab</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Odesivimab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15719</drugbank-id>
      <name>Belantamab mafodotin</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Belantamab mafodotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00039</drugbank-id>
      <name>Palifermin</name>
      <description>The therapeutic efficacy of Palifermin can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00001</drugbank-id>
      <name>Lepirudin</name>
      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00006</drugbank-id>
      <name>Bivalirudin</name>
      <description>The risk or severity of bleeding can be increased when Bivalirudin is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00009</drugbank-id>
      <name>Alteplase</name>
      <description>The risk or severity of bleeding can be increased when Alteplase is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00013</drugbank-id>
      <name>Urokinase</name>
      <description>The risk or severity of bleeding can be increased when Urokinase is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00015</drugbank-id>
      <name>Reteplase</name>
      <description>The risk or severity of bleeding can be increased when Reteplase is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00029</drugbank-id>
      <name>Anistreplase</name>
      <description>The risk or severity of bleeding can be increased when Anistreplase is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00031</drugbank-id>
      <name>Tenecteplase</name>
      <description>The risk or severity of bleeding can be increased when Tenecteplase is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00055</drugbank-id>
      <name>Drotrecogin alfa</name>
      <description>The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00086</drugbank-id>
      <name>Streptokinase</name>
      <description>The risk or severity of bleeding can be increased when Streptokinase is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00278</drugbank-id>
      <name>Argatroban</name>
      <description>The risk or severity of bleeding can be increased when Argatroban is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00569</drugbank-id>
      <name>Fondaparinux</name>
      <description>The risk or severity of bleeding can be increased when Fondaparinux is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01225</drugbank-id>
      <name>Enoxaparin</name>
      <description>The risk or severity of bleeding can be increased when Enoxaparin is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05099</drugbank-id>
      <name>Ancrod</name>
      <description>The risk or severity of bleeding can be increased when Ancrod is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06779</drugbank-id>
      <name>Dalteparin</name>
      <description>The risk or severity of bleeding can be increased when Dalteparin is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06822</drugbank-id>
      <name>Tinzaparin</name>
      <description>The risk or severity of bleeding can be increased when Tinzaparin is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08813</drugbank-id>
      <name>Nadroparin</name>
      <description>The risk or severity of bleeding can be increased when Nadroparin is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09255</drugbank-id>
      <name>Dextran</name>
      <description>The risk or severity of bleeding can be increased when Dextran is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11095</drugbank-id>
      <name>Desirudin</name>
      <description>The risk or severity of bleeding can be increased when Desirudin is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11166</drugbank-id>
      <name>Antithrombin Alfa</name>
      <description>The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11312</drugbank-id>
      <name>Protein C</name>
      <description>The risk or severity of bleeding can be increased when Protein C is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11598</drugbank-id>
      <name>Antithrombin III human</name>
      <description>The risk or severity of bleeding can be increased when Antithrombin III human is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13149</drugbank-id>
      <name>Protein S human</name>
      <description>The risk or severity of bleeding can be increased when Protein S human is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14598</drugbank-id>
      <name>Edetate calcium disodium anhydrous</name>
      <description>The risk or severity of bleeding can be increased when Edetate calcium disodium anhydrous is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09258</drugbank-id>
      <name>Bemiparin</name>
      <description>The risk or severity of bleeding can be increased when Bemiparin is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09260</drugbank-id>
      <name>Parnaparin</name>
      <description>The risk or severity of bleeding can be increased when Parnaparin is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12831</drugbank-id>
      <name>Gabexate</name>
      <description>The risk or severity of bleeding can be increased when Gabexate is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00974</drugbank-id>
      <name>Edetic acid</name>
      <description>The risk or severity of bleeding can be increased when Edetic acid is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09259</drugbank-id>
      <name>Reviparin</name>
      <description>The risk or severity of bleeding can be increased when Reviparin is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00232</drugbank-id>
      <name>Methyclothiazide</name>
      <description>The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00436</drugbank-id>
      <name>Bendroflumethiazide</name>
      <description>The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00562</drugbank-id>
      <name>Benzthiazide</name>
      <description>The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00606</drugbank-id>
      <name>Cyclothiazide</name>
      <description>The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00774</drugbank-id>
      <name>Hydroflumethiazide</name>
      <description>The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00880</drugbank-id>
      <name>Chlorothiazide</name>
      <description>The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00999</drugbank-id>
      <name>Hydrochlorothiazide</name>
      <description>The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01021</drugbank-id>
      <name>Trichlormethiazide</name>
      <description>The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01324</drugbank-id>
      <name>Polythiazide</name>
      <description>The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13430</drugbank-id>
      <name>Mebutizide</name>
      <description>The risk or severity of neutropenia and thrombocytopenia can be increased when Mebutizide is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13532</drugbank-id>
      <name>Cyclopenthiazide</name>
      <description>The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09042</drugbank-id>
      <name>Tedizolid phosphate</name>
      <description>The risk or severity of myelosuppression can be increased when Ibritumomab tiuxetan is combined with Tedizolid phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>Ibritumomab tiuxetan may increase the immunosuppressive activities of Cyclosporine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00115</drugbank-id>
      <name>Cyanocobalamin</name>
      <description>The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00437</drugbank-id>
      <name>Allopurinol</name>
      <description>The risk or severity of adverse effects can be increased when Allopurinol is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15595</drugbank-id>
      <name>Ebola Zaire vaccine (live, attenuated)</name>
      <description>The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14513</drugbank-id>
      <name>Magnesium</name>
      <description>The serum concentration of Magnesium can be decreased when it is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01601</drugbank-id>
      <name>Lopinavir</name>
      <description>The serum concentration of Ibritumomab tiuxetan can be increased when it is combined with Lopinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12530</drugbank-id>
      <name>Inebilizumab</name>
      <description>The risk or severity of infection can be increased when Ibritumomab tiuxetan is combined with Inebilizumab.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;Ibritumomab tiuxetan heavy chain
QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSY
NQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTV
SAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYT
LSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSV
FIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTL
RVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTK
KQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVER
NSYSCSVVHEGLHNHHTTKSFSR</sequence>
    <sequence format="FASTA">&gt;Ibritumomab tiuxetan light chain
QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYAPSNLASGVPAR
FSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGAGTKLELKRADAAPTVFIFPPS
DEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL
SKADYEKHKVYACEVTHQGLSSPVTKSFN</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>61 °C (FAB fragment), 71 °C (whole mAb)</value>
      <source>Vermeer, A.W.P. &amp; Norde, W., Biophys. J. 78:394-404 (2000)</source>
    </property>
    <property>
      <kind>Hydrophobicity</kind>
      <value>-0.359</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>7.91</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>143375.5</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C6382H9830N1672O1979S54</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>12697</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46506112</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>J00470</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164781375</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P01865</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000383</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Ibritumomab_tiuxetan</identifier>
    </external-identifier>
    <external-identifier>
      <resource>RxCUI</resource>
      <identifier>262323</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic3/zevalin.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/ibritumomab-tiuxetan-with-indium-111.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000066</id>
      <name>B-lymphocyte antigen CD20</name>
      <organism>Humans</organism>
      <actions>
        <action>antibody</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A2044</ref-id>
            <pubmed-id>10541376</pubmed-id>
            <citation>Wiseman GA, White CA, Witzig TE, Gordon LI, Emmanouilides C, Raubitschek A, Janakiraman N, Gutheil J, Schilder RJ, Spies S, Silverman DH, Grillo-Lopez AJ: Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody. Clin Cancer Res. 1999 Oct;5(10 Suppl):3281s-3286s.</citation>
          </article>
          <article>
            <ref-id>A2046</ref-id>
            <pubmed-id>11418316</pubmed-id>
            <citation>Goldenberg DM: The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy. Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):195-201.</citation>
          </article>
          <article>
            <ref-id>A2048</ref-id>
            <pubmed-id>11879282</pubmed-id>
            <citation>Dillman RO: Monoclonal antibody therapy for lymphoma: an update. Cancer Pract. 2001 Mar-Apr;9(2):71-80.</citation>
          </article>
          <article>
            <ref-id>A2050</ref-id>
            <pubmed-id>12011122</pubmed-id>
            <citation>Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-Lopez AJ, Multani P, White CA: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002 May 15;20(10):2453-63.</citation>
          </article>
          <article>
            <ref-id>A2052</ref-id>
            <pubmed-id>15045033</pubmed-id>
            <citation>Witzig TE: Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma. Drugs Today (Barc). 2004 Feb;40(2):111-9.</citation>
          </article>
          <article>
            <ref-id>A9</ref-id>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
          <article>
            <ref-id>A2054</ref-id>
            <pubmed-id>20113680</pubmed-id>
            <citation>Goldsmith SJ: Radioimmunotherapy of lymphoma: Bexxar and Zevalin. Semin Nucl Med. 2010 Mar;40(2):122-35. doi: 10.1053/j.semnuclmed.2009.11.002.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P11836" source="Swiss-Prot">
        <name>B-lymphocyte antigen CD20</name>
        <general-function>Mhc class ii protein complex binding</general-function>
        <specific-function>This protein may be involved in the regulation of B-cell activation and proliferation.</specific-function>
        <gene-name>MS4A1</gene-name>
        <locus>11q12</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>57-78
85-105
121-141
189-209</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>4.73</theoretical-pi>
        <molecular-weight>33076.99</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:7315</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>MS4A1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X12530</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>29774</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2628</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P11836</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CD20_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>B-lymphocyte surface antigen B1</synonym>
          <synonym>Bp35</synonym>
          <synonym>CD20</synonym>
          <synonym>Leukocyte surface antigen Leu-16</synonym>
          <synonym>Membrane-spanning 4-domains subfamily A member 1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000132|B-lymphocyte antigen CD20
MTTPRNSVNGTFPAEPMKGPIAMQSGPKPLFRRMSSLVGPTQSFFMRESKTLGAVQIMNG
LFHIALGGLLMIPAGIYAPICVTVWYPLWGGIMYIISGSLLAATEKNSRKCLVKGKMIMN
SLSLFAAISGMILSIMDILNIKISHFLKMESLNFIRAHTPYINIYNCEPANPSEKNSPST
QYCYSIQSLFLGILSVMLIFAFFQELVIAGIVENEWKRTCSRPKSNIVLLSAEEKKEQTI
EIKEEVVGLTETSSQPKNEEDIEIIPIQEEEEEETETNFPEPPQDQESSPIENDSSP</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0009913|B-lymphocyte antigen CD20 (MS4A1)
ATGACAACACCCAGAAATTCAGTAAATGGGACTTTCCCGGCAGAGCCAATGAAAGGCCCT
ATTGCTATGCAATCTGGTCCAAAACCACTCTTCAGGAGGATGTCTTCACTGGTGGGCCCC
ACGCAAAGCTTCTTCATGAGGGAATCTAAGACTTTGGGGGCTGTCCAGATTATGAATGGG
CTCTTCCACATTGCCCTGGGGGGTCTTCTGATGATCCCAGCAGGGATCTATGCACCCATC
TGTGTGACTGTGTGGTACCCTCTCTGGGGAGGCATTATGTATATTATTTCCGGATCACTC
CTGGCAGCAACGGAGAAAAACTCCAGGAAGTGTTTGGTCAAAGGAAAAATGATAATGAAT
TCATTGAGCCTCTTTGCTGCCATTTCTGGAATGATTCTTTCAATCATGGACATACTTAAT
ATTAAAATTTCCCATTTTTTAAAAATGGAGAGTCTGAATTTTATTAGAGCTCACACACCA
TATATTAACATATACAACTGTGAACCAGCTAATCCCTCTGAGAAAAACTCCCCATCTACC
CAATACTGTTACAGCATACAATCTCTGTTCTTGGGCATTTTGTCAGTGATGCTGATCTTT
GCCTTCTTCCAGGAACTTGTAATAGCTGGCATCGTTGAGAATGAATGGAAAAGAACGTGC
TCCAGACCCAAATCTAACATAGTTCTCCTGTCAGCAGAAGAAAAAAAAGAACAGACTATT
GAAATAAAAGAAGAAGTGGTTGGGCTAACTGAAACATCTTCCCAACCAAAGAATGAAGAA
GACATTGAAATTATTCCAATCCAAGAAGAGGAAGAAGAAGAAACAGAGACGAACTTTCCA
GAACCTCCCCAAGATCAGGAATCCTCACCAATAGAAAATGACAGCTCTCCTTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF04103</identifier>
            <name>CD20</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>external side of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>MHC class II protein complex binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>B cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>humoral immune response</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>